Cytokinetics Email Format
Biotechnology ResearchCalifornia, United States501-1000 Employees
Cytokinetics is a mid-sized biotechnology company based in South San Francisco, California, focused on advancing therapies that modulate muscle function. It concentrates on first-in-class muscle activators and next-in-class muscle inhibitors intended to treat debilitating diseases where muscle performance is compromised or declines. The company targets patients and clinicians dealing with muscle-related conditions, leveraging its expertise in muscle biology and contractility to develop small-molecule drug candidates. In June 2026 Cytokinetics announced the first commercial European launch of MYQORZO (aficamten) in Germany, marking a broader geographic presence for its therapy.